Pulmatrix, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pulmatrix, Inc. on June 15, 2015. The filing primarily discloses the entry into a material definitive agreement involving a new credit facility and the issuance of unregistered equity securities. Additionally, the company announced strategic developments regarding its clinical-stage drug candidates.
Key Financial Metrics and Obligations
- Debt Financing: Entered into a term loan agreement with a principal amount of $7,000,000, fully funded on June 16, 2015.
- Interest Rate: Floating annual rate equal to the greater of 9.50% or (Prime Rate minus 3.25% plus 8.50%).
- Repayment Terms: Interest-only payments begin July 1, 2015. Principal amortization begins August 1, 2016, over 30 months. Final maturity date is July 1, 2018.
- End of Term Charge: A fee of $245,000 is due upon repayment of the term loan.
- Collateral: The facility is secured by substantially all assets of the company and its subsidiary, excluding intellectual property.
- Equity Issuance: Issued a warrant to Hercules Technology Growth Capital, Inc. to purchase up to 25,150 shares of common stock at an exercise price of $8.35 per share, expiring June 16, 2020.
- Conversion Option: Up to $1,000,000 of principal may be converted into common stock at a fixed price of $11.73 per share (post reverse split), subject to market price conditions.
Material Changes and Covenants
The filing represents a significant change in the company's capital structure through the addition of $7 million in debt. The credit facility imposes strict affirmative and negative covenants, including:
- Prohibition on repurchasing or redeeming capital stock.
- Prohibition on declaring or paying cash dividends or making cash distributions.
- Restrictions on incurring additional indebtedness, mergers, acquisitions, and asset sales.
- Requirement to maintain legal existence, governmental approvals, and insurance coverage.
Events of default include failure to pay, breach of covenants, insolvency, or material adverse effects, which could trigger foreclosure on collateral, including cash.
Outlook, Management Commentary, and Unusual Items
While the filing does not provide specific financial guidance or management commentary on future earnings, it highlights two significant business developments announced via press release on June 16, 2015:
- PUR0200: An agreement with Mylan N.V. for the development of this clinical-stage bronchodilator therapy candidate.
- PUR1900: Announcement of a new drug candidate, an inhaled anti-infective intended to treat fungal infections associated with cystic fibrosis.
The filing notes that the term loan and warrant issuance were exempt from registration under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Investor Verification Checklist
- Verify the current status of the $7 million term loan and whether any prepayment fees apply if refinancing is considered.
- Confirm the impact of the negative covenants on the company's ability to raise future equity or pay dividends.
- Review the progress of the PUR0200 development agreement with Mylan N.V. and the clinical timeline for PUR1900.
- Monitor the company's cash burn rate to ensure compliance with interest-only payments starting July 1, 2015.
- Check for any subsequent filings regarding the potential conversion of debt to equity at the $11.73 fixed price.